Yes, and thank you very much for the question. Also, thank you for the kind words with respect to the work in terms of market access.
During that period, typically at the early research stage, there is little interaction, because the company at that point is finding out if they have something that will have mileage. Once they believe they do, that's typically when interaction starts. We encourage that interaction, but it isn't mandatory.
It's entirely possible for a company to go through all of that process and come to us only when they're ready to come to market. It's not the wisest decision in the world, and the reason for that is that when we have questions during the review process, the review stops. We go back to companies with questions in terms of deficiency letters, and, in essence, if they haven't had a lot of interaction with us, it can sometimes take them almost a year to compile the necessary data just to answer those questions.
For the efficiency of the system, we would rather reduce that cycle time, because if a company is coming to us with what they believe to be a legitimate market opportunity, then we're interested in carrying out the due diligence in a time frame that can give some predictability for market entry. That's why we encourage that interaction.
That interaction typically takes place less in the pure development end of the research and more in the market preparation end as they are compiling the regulatory data, as opposed to the research to develop, for example, the AquAdvantage. As they move to something that they think is going to work, what do they need to do to be able to demonstrate that it's safe? It's not whether they can get it to to grow at an accelerated pace, but rather, now that it seems to be working, what do they need to do to get it into the market? That's where the significant interaction helps.